Amodiaquine
From Wikipedia, the free encyclopedia
 |
|
|
Amodiaquine
|
|
| Systematic (IUPAC) name | |
| 4-[(7-chloroquinolin-4-yl)amino]-2-[(diethylamino)methyl]phenol | |
| Identifiers | |
| CAS number | |
| ATC code | P01 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C20H22ClN3O |
| Mol. mass | 355.861 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | 5.2 ± 1.7 (range 0.4 to 5.5) minutes |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Amodiaquine (trade names Camoquin, Flavoquine) is a 4-aminoquinoline compound related to chloroquine, used as an antimalarial and anti-inflammatory agent.
Amodiaquine has been shown to be more effective than chloroquine in treating CRPF (chloroquine-resistant Plasmodium falciparum) malaria infections and may afford more protection than chloroquine when used as weekly prophylaxis. Amodiaquine, like chloroquine, is generally well tolerated. Although licensed, this drug is not marketed in the United States but is widely available in Africa. Its use, therefore, is probably more practicable in long-term visitors and persons who will reside in Africa.[1]
[edit] Notes
|
||||||||||||||||||||
 |
This antimicrobial-related article is a stub. You can help Wikipedia by expanding it. |
